SLAMF7 and neoplasm: These results are supported by the previous reports which demonstrated that elotuzumab could change the immune-suppressive tumor microenvironment to enhance anti-tumor effect by blocking SLAMF7 signaling and eliminating immunosuppressive T cells30–32.